<DOC>
	<DOCNO>NCT00031928</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial determine effectiveness mafosfamide treat patient progressive refractory meningeal tumor .</brief_summary>
	<brief_title>Mafosfamide Treating Patients With Progressive Refractory Meningeal Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine qualitative quantitative toxicity mafosfamide patient progressive refractory meningeal malignancy . - Determine maximum tolerate dose drug patient . - Determine cerebrospinal fluid pharmacokinetics drug patient . OUTLINE : This dose-escalation , multicenter study . Patients receive intrathecal mafosfamide 20 minute twice weekly 6 week ( induction therapy ) . Patients receive intrathecal mafosfamide weekly 4 week ( consolidation therapy ) , twice month 4 month , monthly thereafter ( maintenance therapy ) absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos mafosfamide maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 3000 patient accrue study .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Mafosfamide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis leukemia lymphoma meningeal involvement define cerebrospinal fluid cell count least 5/mm^3 AND evidence blast cell cytospin preparation cytology OR Diagnosis solid tumor meningeal involvement define presence tumor cell cytospin preparation cytology OR presence measurable meningeal disease CT MRI scan Meningeal malignancy must progressive refractory conventional therapy Meningeal malignancy secondary underlie solid tumor allow initial diagnosis provide conventional therapy No concurrent bone marrow relapse leukemia lymphoma patient No clinical evidence obstructive hydrocephalus compartmentalization cerebrospinal fluid flow document radioisotope indium In 111 technetium Te 99DTPA flow study Patients demonstrate restore flow focal radiotherapy allow PATIENT CHARACTERISTICS : Age : Over 3 Performance status : ECOG 02 Life expectancy : At least 8 week Hematopoietic : Not specify Hepatic : No clinically significant liver function abnormalities Renal : No clinically significant renal function abnormalities Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No clinically significant metabolic parameter abnormality ( e.g. , electrolytes , calcium , phosphorus ) No significant systemic illness ( e.g. , infection ) PRIOR CONCURRENT THERAPY : Biologic therapy : Recovered prior immunotherapy Chemotherapy : At least 1 week since prior intrathecal chemotherapy ( 2 week cytarabine ( liposomal ) ) recover Concurrent systemic chemotherapy control systemic bulk CNS disease allow following exception : No phase I agent No agent significantly penetrate CNS ( e.g. , highdose systemic methotrexate ( 1 g/m^2 ) , highdose cytarabine ( 2 g/m^2 ) , IV mercaptopurine , fluorouracil , topotecan , thiotepa ) No agent know serious unpredictable CNS side effect Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Recovered prior radiotherapy At least 8 week since prior craniospinal irradiation Local radiotherapy symptomatic bulky CNS disease must give prior induction therapy No concurrent whole brain craniospinal irradiation Concurrent partial brain ( e.g. , base brain ) limitedfield spinal radiotherapy asymptomatic bulky ( radiographically visible ) CNS disease allow Total CNS radiotherapy dose must exceed accept safe tissue tolerance Surgery : Not specify Other : At least 1 week since prior CNS therapy At least 7 day since prior intrathecal investigational agent At least 14 day since prior systemic investigational agent No concurrent intrathecal systemic investigational agent No concurrent intrathecal systemic therapy treat meningeal malignancy No concurrent intrathecal therapy agent significantly penetrate bloodbrain barrier No concurrent agent know serious unpredictable CNS side effect</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2003</verification_date>
	<keyword>leptomeningeal metastasis</keyword>
</DOC>